Sildenafil and FDP-Sr attenuate diabetic cardiomyopathy by suppressing abnormal expression of myocardial CASQ2, FKBP12.6, and SERCA2a in rats

Acta Pharmacologica Sinica

Volumn 32, Issue 4, 2011, Pages 441-448

  Cheng, Yu Si ^a   Dai, De Zai ^a   Ji, Hui ^a   Zhang, Qi ^b   Dai, Yin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

Author keywords

calcium homeostasis; CASQ2; diabetic cardiomyopathy; FDP Sr; FKBP12.6; SERCA2a; sildenafil; testosterone

Indexed keywords

BIOLOGICAL MARKER; CALSEQUESTRIN; CHOLESTEROL; FATTY ACID; FK 506 BINDING PROTEIN; FRUCTOSE BISPHOSPHATE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSINATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PROTEIN KINASE C EPSILON; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SILDENAFIL; STREPTOZOCIN; TESTOSTERONE PROPIONATE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CALCIUM HOMEOSTASIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEART VENTRICLE HYPERTROPHY; MALE; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANDROGENS; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; DIABETIC CARDIOMYOPATHIES; FRUCTOSE; HOMEOSTASIS; LIPID METABOLISM; MALE; MYOCARDIUM; OXIDATIVE STRESS; PHOSPHODIESTERASE 4 INHIBITORS; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SULFONES; TACROLIMUS BINDING PROTEINS;

EID: 79953782637     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.226     Document Type: Article

References (38)

1. Lebeche D, Davidoff AJ, Hajjar RJ. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008; 5: 715-24.
2. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 2008; 121: 748-57.
3. Asghar O, Al-Sunni A, Khavandi K, Khavandi A, Withers S, Greenstein A, et al. Diabetic cardiomyopathy. Clin Sci (Lond) 2009; 116: 741-60.
4. Montagnani M. Diabetic cardiomyopathy: how much does it depend on AGE? Br J Pharmacol 2008; 154: 725-26. (Pubitemid 351821582)
5. Tang M, Zhong M, Shang Y, Lin H, Deng J, Jiang H, et al. Differential regulation of collagen types I and III expression in cardiac fibroblasts by AGEs through TRB3/MAPK signaling pathway. Cell Mol Life Sci 2008; 65: 2924-32.
6. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci (Lond) 2004; 107: 539-57. (Pubitemid 39627201)
7. 2+-ATPase. Diabetes 2004; 53: 463-73. (Pubitemid 38174564)
8. Qi MY, Xia HJ, Dai DZ, Dai Y. A novel endothelin receptor antagonist CPU0213 improves diabetic cardiac insufficiency attributed to upregulation of the expression of FKBP12.6, SERCA2a, and PLB in rats. J Cardiovasc Pharmacol 2006; 47: 729-35. (Pubitemid 44305245)
9. Qi MY, Liu HR, Dai DZ, Li N, Dai Y. Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats. J Pharm Pharmacol 2008; 60: 1687-94.
10. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-23. (Pubitemid 47012236)
11. Györke S. Molecular basis of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2009; 6: 123-9.
12. Li N, Jia N, Dai DZ, Hu C, Dai Y. Role of endothelin in the effects of isoprenaline on potassium currents and calsequestrin 2 expression in the heart. Clin Exp Pharmacol Physiol 2010; 37: 557-63.
13. Maggio M, Basaria S. Welcoming low testosterone as a cardiovascular risk factor. Int J Impot Res 2009; 21: 261-4.
14. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010; 21: 496-503.
15. Francomano D, Bruzziches R, Natali M, Aversa A, Spera G. Cardiovascular effect of testosterone replacement therapy in aging male. Acta Biomed 2010; 81: 101-6.
16. Mancini A, Leone E, Festa R, Grande G, Silvestrini A, de Marinis L, et al. Effects of testosterone on antioxidant systems in male secondary hypogonadism. J Androl 2008; 29: 622-9.
17. Montani D, Chaumais MC, Savale L, Natali D, Price LC, Jaïs X, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009; 26: 813-25.
18. Guazzi M. Sildenafil and phosphodiesterase-5 inhibitors for heart failure. Curr Heart Fail Rep 2008; 5: 110-4.
19. Zhang Q, Liu HR, Ying HJ, Dai DZ, Tang XY, Dai Y. Strontium fructose 1,6-diphosphate early diabetic testopathy by suppressing abnormal testicular matrix metalloproteinase system in streptozocin-treated rats. J Pharm Pharmacol 2009; 61: 229-36.
20. Xu M, Dai DZ, Zhang Q, Cheng YS, Dai Y. Upregulated NADPH oxidase contributes to diabetic testicular complication and is relieved by strontium fructose 1,6-diphosphate. Exp Clin Endocrinol Diabetes 2010; 118: 459-65.
21. Cheng YS, Dai DZ, Dai Y. Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin. J Pharm Pharmacol 2009; 61: 569-76.
22. Na T, Dai DZ, Tang XY, Dai Y. Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 39-49. (Pubitemid 46354557)
23. Casey RW, Barkin J. Testosterone replacement therapy for the primary care physician. Can J Urol 2008; 15: 71-7.
24. Bilginoglu A, Seymen A, Tuncay E, Zeydanli E, Aydemir-Koksoy A, Turan B. Antioxidants but not doxycycline treatments restore depressed beta-adrenergic responses of the heart in diabetic rats. Cardiovasc Toxicol 2009; 9: 21-9.
25. Adeghate E. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol Cell Biochem 2004; 261: 187-91. (Pubitemid 39004531)
26. Violi F, Basili S, Nigro C, Pignatelli P. Role of NADPH oxidase in atherosclerosis. Future Cardiol 2009; 5: 83-92.
27. Münzel T. Endothelial dysfunction: pathophysiology, diagnosis and prognosis. Dtsch Med Wochenschr 2008; 133: 2465-70.
28. Rajesh M, Mukhopadhyay P, Bátkai S, Mukhopadhyay B, Patel V, Haskó G, et al. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med 2009; 13: 2330-41.
29. Iciek R, Wender-Ozegowska E, Seremak-Mrozikiewicz A, Drews K, Brazert J, Pietryga M. Leptin gene, leptin gene receptor polymorphisms and body weight in pregnant women with type 1 diabetes mellitus. Ginekol Pol 2008; 79: 592-601.
30. Zhang Y, Huang ZJ, Dai DZ, Feng Y, Na T, Tang XY, et al. Downregulated FKBP12.6 expression and upregulated endothelin signaling contribute to elevated diastolic calcium and arrhythmogenesis in rat cardiomyopathy produced by L-thyroxin. Int J Cardiol 2008; 130: 463-71.
31. Liu N, Rizzi N, Boveri L, Priori SG. Ryanodine receptor and calsequestrin in arrhythmogenesis: what we have learnt from genetic diseases and transgenic mice. J Mol Cell Cardiol 2009; 46: 149-59.
32. 2+ signaling in the heart. J Clin Invest 2007; 117: 1758-62. (Pubitemid 47036309)
33. Song L, Alcalai R, Arad M, Wolf CM, Toka O, Conner DA, et al. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 2007; 117: 1814-23. (Pubitemid 47036315)
34. Li N, Jia N, Dai DZ, Hu C, Dai Y. Role of endothelin in the effects of isoprenaline on potassium currents and calsequestrin 2 expression in the heart. Clin Exp Pharmacol Physiol 2010; 37: 557-63
35. Li N, Jia N, Dai DZ, Dai Y. Endothelin receptor antagonist CPU0213 and vitamin E reverse downregulation of FKBP12.6 and SERCA2a: a role of hyperphosphorylation of PKCepsilon. Eur J Pharmacol 2008; 591: 211-8.
36. Min W, Bin ZW, Quan ZB, Hui ZJ, Sheng FG. The signal transduction pathway of PKC/NF-kappaB/c-fos may be involved in the influence of high glucose on the cardiomyocytes of neonatal rats. Cardiovasc Diabetol 2009; 8: 8.
37. Cheng YS, Dai DZ, Dai Y. Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCepsilon in the heart, which are mitigated by endothelin receptor antagonist CPU0213. Acta Pharmacol Sin 2009; 30: 1099-106.
38. Zheng YF, Dai DZ, Dai Y. NaHS ameliorates diabetic vascular injury by correcting depressed connexin 43 and 40 in the vasculature in streptozotocin-injected rats. J Pharm Pharmacol 2010; 62: 615-21.